<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-658" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Betaxolol</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tajran</surname>
            <given-names>Jahan</given-names>
          </name>
          <aff>Wayne St. University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Goyal</surname>
            <given-names>Anju</given-names>
          </name>
          <aff>Wayne State University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jahan Tajran declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anju Goyal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-658.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Betaxolol is an FDA-approved medication with applications in open-angle glaucoma, essential hypertension, post-myocardial infarction, and chronic stable angina. Classified as a selective &#x003b2;-1 adrenergic blocker, betaxolol distinguishes itself through ophthalmic and oral formulations tailored for specific therapeutic purposes. This course&#x000a0;explores betaxolol, emphasizing its indications, mechanism of action, and contraindications, particularly for open-angle glaucoma and essential hypertension. Through an in-depth review of current literature, healthcare professionals will gain a thorough understanding of betaxol's pharmacology and clinical efficacy, enabling them to make informed decisions and effective interventions for optimal patient outcomes.</p>
        <p>Additionally, this&#x000a0;curse explores off-label uses, dosing strategies, monitoring protocols, clinical toxicology considerations, and relevant drug interactions. By providing healthcare professionals with this essential knowledge, this educational initiative empowers them to address glaucoma and essential hypertension with betaxolol pharmacotherapy adeptly. Through a robust examination of the medication's intricacies, participants will be well-equipped to navigate the complexities of betaxolol administration, ensuring that patients receive optimal care and benefit from this versatile therapeutic option.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of betaxolol.</p></list-item><list-item><p>Assess the adverse drug reactions of betaxolol.</p></list-item><list-item><p>Implement&#x000a0;the appropriate monitoring strategies for patients receiving betaxolol.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from betaxolol pharmacotherapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=658&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=658">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-658.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Betaxolol is a lipophilic &#x003b2;-adrenergic blocker selective to the &#x003b2;-1 adrenergic receptor, with a limited &#x003b2;-2 blocking effect. This factor is an important distinction compared to topical nonselective &#x003b2;-blockers.<xref ref-type="bibr" rid="article-658.r1">[1]</xref><xref ref-type="bibr" rid="article-658.r2">[2]</xref>&#x000a0;Betaxolol can be administered by topical (ophthalmic) or systemic (oral) routes.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Topical betaxolol is FDA-approved for ocular hypertension and chronic open-angle glaucoma.<xref ref-type="bibr" rid="article-658.r1">[1]</xref><xref ref-type="bibr" rid="article-658.r2">[2]</xref><xref ref-type="bibr" rid="article-658.r3">[3]</xref>&#x000a0;Glaucoma is an optic neuropathy defined by the death of retinal ganglion cells and characteristic changes to the optic nerve head. Intraocular pressure, as well as other factors, are factors for the loss of ganglion cells. Beta-blockers like betaxolol were once the first-line treatment for open-angle glaucoma, but now topical prostaglandin analogs, like latanoprost, are the drugs of choice. This change in prescribing is because even in the topical form, &#x003b2;-blockers have more systemic adverse effects than prostaglandin analogs.<xref ref-type="bibr" rid="article-658.r4">[4]</xref><xref ref-type="bibr" rid="article-658.r5">[5]</xref><xref ref-type="bibr" rid="article-658.r6">[6]</xref>&#x000a0;Beta-blockers are used when prostaglandins are not tolerated and additional intraocular pressure reduction is indicated. Betaxolol is indicated when a patient has mild respiratory comorbidity like asthma or COPD. Betaxolol&#x02019;s selective &#x003b2;-1 adrenergic blockade decreases the likelihood of systemic and respiratory adverse effects compared to nonselective &#x003b2;-blockers like timolol.<xref ref-type="bibr" rid="article-658.r2">[2]</xref><bold>&#x000a0;</bold>The American Academy of Ophthalmology endorses betaxolol as a potential treatment option for primary open-angle glaucoma.<xref ref-type="bibr" rid="article-658.r7">[7]</xref></p>
        <p>Oral betaxolol is FDA-approved for essential hypertension, post-myocardial infarction, and chronic stable angina.<xref ref-type="bibr" rid="article-658.r8">[8]</xref>&#x000a0;Similar to the other &#x003b2;-1 selective &#x003b2;-blockers, betaxolol is associated with a decreased risk of stroke, congestive heart failure, and coronary artery disease. Betaxolol also demonstrates reduced mortality and morbidity post-myocardial infarction. The American Heart Association/American College of Cardiology guidelines (AHA/ACC) published in 2023 state that &#x003b2;-blockers are especially effective in chronic coronary disease, especially in recent myocardial infarction and ongoing angina. The beneficial effect is due to their ability to reduce angina, exertion-related myocardial ischemia, and the risk of cardiovascular events.<xref ref-type="bibr" rid="article-658.r9">[9]</xref>&#x000a0;AHA/ACC guidelines for hypertension note that &#x003b2;-blockers are not recommended as first-line agents in the treatment unless the patient has ischemic heart disease or heart failure.<xref ref-type="bibr" rid="article-658.r8">[8]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>The non-FDA-approved uses for betaxolol include essential tremors, migraine prophylaxis, and anxiety disorders. However, other agents, such as propranolol, are preferred for migraine prophylaxis and essential tremor.<xref ref-type="bibr" rid="article-658.r3">[3]</xref><xref ref-type="bibr" rid="article-658.r10">[10]</xref>&#x000a0;One study showed topical betaxolol is effective for relapsing paronychia, also known as a skin infection around a fingernail. Further research is required to validate these findings.<xref ref-type="bibr" rid="article-658.r11">[11]</xref></p>
      </sec>
      <sec id="article-658.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Betaxolol selectively antagonizes &#x003b2;-1 receptors. The adrenergic receptors are located primarily in the kidney, cardiac myocytes, nodal tissue, and other cardiac conduction tissue.<xref ref-type="bibr" rid="article-658.r12">[12]</xref>&#x000a0;Specifically, &#x003b2;-1 receptors are G-protein-coupled receptors that activate cyclic AMP (cAMP) through a cascade of events. Cyclic AMP activation interacts with cAMP-dependent protein kinases, increasing calcium ion&#x000a0;concentration. This increase in calcium leads to different physiological changes depending on the location of the receptor.&#x000a0;Betaxolol reduces the heart rate and myocardial contractility, lowering blood pressure and myocardial oxygen demand. The &#x003b2;-blockade also affects the atrioventricular node by reducing conduction and increasing AV nodal refractory time. Additionally, its impact on juxtaglomerular cells of the kidney reduces renin release, reducing angiotensin I levels and effectively lowering blood pressure.<xref ref-type="bibr" rid="article-658.r13">[13]</xref></p>
        <p>The precise cause of glaucoma is not completely understood, yet the regulation of intraocular pressure engages&#x000a0;2 independent pathways: the trabecular meshwork and the uveoscleral pathway. In primary open-angle glaucoma, there is increased resistance to the outflow of aqueous humor, a clear fluid produced by the ciliary bodies, through the trabecular meshwork. This action increases intraocular pressure, leading to the degeneration of retinal ganglion cells and the optic nerve over time, causing progressive vision loss that typically starts at the periphery and can expand to involve the whole field of vision for that eye. Patients with normal intraocular pressure can also develop glaucoma. Increased calcium in the ciliary body leads to increased aqueous humor production, which can cause elevated intraocular pressure, as seen in glaucoma. Betaxolol prevents the G-protein cascade from increasing intracellular calcium, thus preventing aqueous humor production from the ciliary body.<xref ref-type="bibr" rid="article-658.r3">[3]</xref><xref ref-type="bibr" rid="article-658.r4">[4]</xref><xref ref-type="bibr" rid="article-658.r12">[12]</xref></p>
        <p>Betaxolol is rarely associated with bronchospasm, sometimes seen in nonselective &#x003b2;-blockers like timolol. Beta-2 receptors are present in bronchial and vascular smooth muscle; this explains betaxolol's preferred use over nonselective &#x003b2;-blockers, like timolol, in those with mild comorbid respiratory pathologies and contraindications to other therapeutic options.<xref ref-type="bibr" rid="article-658.r7">[7]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Oral betaxolol demonstrates good absorption. A consistent first-pass effect leads to a bioavailability of 89% &#x000b1; 5%, unaffected by food or alcohol intake. Peak blood concentrations typically occur between 1.5 and 6 hours, with a mean of 3 hours. The steady-state plasma levels are usually achieved within 5 to 7 days with once-daily dosing in patients with normal renal function. The onset of action of betaxolol ophthalmic solution is typically noted within 30 minutes of application, reaching its peak effect around 2 hours post-administration. A single dose usually leads to a 12-hour reduction in intraocular pressure.</p>
        <p><bold>Distribution:</bold> Betaxolol exhibits approximately 50% binding to plasma proteins. Topical application of betaxolol results in higher concentrations primarily in anterior segment tissues, notably in the iris and ciliary body. Comparatively lower concentrations are observed in posterior segment tissues, including the choroid, retina, optic nerve head, optic nerve, and vitreous humor.<xref ref-type="bibr" rid="article-658.r14">[14]</xref>&#x000a0;The lipophilicity of betaxolol is more than that of timolol, resulting in enhanced distribution across ocular structures.<xref ref-type="bibr" rid="article-658.r15">[15]</xref></p>
        <p><bold>Metabolism:</bold> Betaxolol is primarily metabolized in the liver. Betaxolol is a minor substrate of CYP1A2 and CYP2D6 and an inhibitor of CYP2D6.<xref ref-type="bibr" rid="article-658.r16">[16]</xref></p>
        <p><bold>Elimination:</bold> The mean elimination half-life after single oral doses ranges from approximately 14 to 22 hours. Following oral administration, over 80% of the administered betaxolol dose is excreted in the urine as betaxolol and its metabolite. The half-life and area under the curve increase in renal impairment, necessitating a lower initial dosage.</p>
      </sec>
      <sec id="article-658.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Adult Dosage, Dosage Forms, and Strengths</bold>
</p>
        <p>Betaxolol has received FDA approval as an oral tablet (10 mg, 20 mg) and an ophthalmic solution (0.5%).</p>
        <p>Ophthalmic: Betaxolol is administered topically as a 0.5% betaxolol hydrochloride ophthalmic solution for ocular hypertension and open-angle glaucoma. The current guidelines recommend&#x000a0;1 drop of 0.5% betaxolol hydrochloride ophthalmic solution twice daily in the affected eye(s). This dosing equates to approximately&#x000a0;28 &#x003bc;g/d. A stabilization in the decrease in intraocular pressure should be observed within a few weeks. If the desired response does not occur,&#x000a0;clinicians can consider adding other medications to the treatment regimen.<xref ref-type="bibr" rid="article-658.r17">[17]</xref></p>
        <p>Oral: For the treatment of hypertension, betaxolol is administered orally at a starting dosage of 10 mg at bedtime. Betaxolol is either used as monotherapy or in combination with a diuretic. If the desired antihypertensive response does not occur within 7 to 14 days, the clinician can consider increasing the dosage of betaxolol. According to the AHA/ACC guidelines, the recommended dosage range for hypertension with betaxolol is 5 to 20 mg.<xref ref-type="bibr" rid="article-658.r8">[8]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment</bold>: Notable alterations in the clearance of betaxolol are generally not observed in hepatic impairment. Therefore, routine adjustments to the dosage are typically unnecessary. No specified dosage adjustments are provided in the product labeling for betaxolol ophthalmic solution.</p>
        <p><bold>Renal impairment</bold>: The clearance of betaxolol diminishes in renal impairment. The initial suggested dosage of betaxolol tablets is 5 mg once daily for severe renal impairment or during dialysis. If the desired response is not achieved, the dosage of betaxolol can be increased by 5 mg daily every&#x000a0;2 weeks, up to a maximum daily&#x000a0;dosage of 20 mg. No specified dosage adjustments are provided in the product labeling for betaxolol ophthalmic solution.</p>
        <p><bold>Pregnancy</bold>
<bold>considerations</bold>: Betaxolol is classified by the FDA as Pregnancy Category C. There is a lack of sufficient and well-controlled studies concerning betaxolol in pregnancy. Betaxolol administration during pregnancy resulted in malformations in animal studies, including increased postimplantation loss and developmental abnormalities. The use of betaxolol during pregnancy should only be considered if the potential benefit justifies potential fetal risks. Beta-blockers, including betaxolol, may reduce placental perfusion, potentially resulting in intrauterine fetal death, immature or premature deliveries, and adverse effects, notably hypoglycemia and bradycardia, in the fetus. As per the American College of Obstetricians and Gynecologists guidelines, labetalol or nifedipine is recommended for chronic hypertension in pregnancy.<xref ref-type="bibr" rid="article-658.r18">[18]</xref>&#x000a0;Clinicians should consider betaxolol ophthalmic solution during pregnancy only after careful risk-benefit analysis.</p>
        <p><bold>Breastfeeding</bold>
<bold>considerations</bold>:&#x000a0;Considering the significant excretion of betaxolol into breast milk and limited experience during breastfeeding, alternative &#x003b2;-blocking agents may be preferable for systemic use, especially while nursing newborns or preterm infants. Topical application of betaxolol in the mother's eyes poses minimal risk to the breastfed infant. Apply pressure to the tear duct near the eye's corner for at least&#x000a0;1 minute to reduce the amount of betaxolol reaching breastmilk after administering eye drops. Remove any excess solution using an absorbent tissue.<xref ref-type="bibr" rid="article-658.r19">[19]</xref></p>
        <p><bold>Pediatric</bold>
<bold>patients</bold>:&#x000a0;The safety and efficacy of oral/ophthalmic betaxolol in pediatric patients have not been established.</p>
        <p><bold>Older</bold>
<bold>patients</bold>:&#x000a0;Clinicians should consider starting betaxolol at a reduced dosage of 5 mg in older patients due to the potential for &#x003b2;-blocker-induced bradycardia.</p>
      </sec>
      <sec id="article-658.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Betaxolol has both local and systemic adverse effects. The ocular adverse drug reactions include transient irritation (25% to 40%), burning, pruritus, punctate keratitis, and blurry vision. Compared to topical timolol (a nonselective &#x003b2;-blocker), betaxolol showed a higher incidence of ocular adverse effects. Compared to nonselective topical &#x003b2;-adrenergic receptor blockers, betaxolol&#x000a0;is less likely to cause adverse effects on pulmonary function. However, betaxolol use still requires caution in patients with underlying pulmonary disease. Symptomatic pulmonary obstruction due to betaxolol has been reported in patients with underlying asthma or chronic obstructive pulmonary disease. A post-marketing study in the United States identified 56 spontaneous adverse effect reports, with 8 cases requiring hospitalization due to asthma exacerbation.<xref ref-type="bibr" rid="article-658.r2">[2]</xref><xref ref-type="bibr" rid="article-658.r3">[3]</xref><xref ref-type="bibr" rid="article-658.r4">[4]</xref></p>
        <p>The systemic adverse effects are often seen in the oral form but can also occur with the topical administration of betaxolol. Although betaxolol is considered a &#x0201c;selective&#x0201d; beta-blocker, it loses its selective binding at higher doses and starts to antagonize &#x003b2;-2 and &#x003b2;-3 receptors. Some of the systemic adverse effects include bradycardia, hypotension, fatigue, sexual impotence, hair loss, confusion, headache, dizziness, and bronchospasm at higher doses. Other cardiac problems like arrhythmia, bundle branch block, myocardial infarction, sinus arrest, and congestive heart failure have also been reported in association with betaxolol use. Additional adverse effects reported are depression, disorientation, vertigo, sleepwalking, rhinitis, dysuria, alopecia, and prolonged prothrombin time.<xref ref-type="bibr" rid="article-658.r2">[2]</xref>&#x000a0;Betaxolol and the other &#x003b2;-blockers can cause metabolic adverse effects like an increase in LDL cholesterol levels and, most notably, can dangerously mask the symptoms of hypoglycemia (ie, tachycardia) in&#x000a0;patients with diabetes.<xref ref-type="bibr" rid="article-658.r3">[3]</xref><xref ref-type="bibr" rid="article-658.r20">[20]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Catecholamine-depleting medications: Reserpine can significantly reduce blood pressure.<xref ref-type="bibr" rid="article-658.r21">[21]</xref>&#x000a0;Patients treated with both a &#x003b2;-blocker and a catecholamine depletor should be closely monitored for signs of hypotension or pronounced bradycardia, which could result in vertigo, syncope, or postural hypotension.</p>
        <p>Clonidine: Discontinuation syndrome may occur when clonidine is suddenly stopped while using a &#x003b2;-blocker, causing rebound hypertension due to a surge in catecholamines. When discontinuing therapy in patients concurrently taking betaxolol and clonidine, the &#x003b2;-blocker should be gradually tapered over several days before withdrawing clonidine.<xref ref-type="bibr" rid="article-658.r22">[22]</xref></p>
        <p>Calcium channel blockers: The risk of left ventricular failure and AV conduction abnormalities, which can lead to complete heart block, is often associated with the simultaneous administration of &#x003b2;-blockers like betaxolol and verapamil or diltiazem.<xref ref-type="bibr" rid="article-658.r23">[23]</xref></p>
        <p>Digoxin: Both digitalis glycosides and betaxolol can slow atrioventricular conduction and reduce heart rate, increasing the risk of bradycardia.<xref ref-type="bibr" rid="article-658.r24">[24]</xref></p>
        <p>Antiarrhythmic medications: Amiodarone, an antiarrhythmic agent, exhibits negative chronotropic properties that may augment the effects of betaxolol.<xref ref-type="bibr" rid="article-658.r25">[25]</xref>&#x000a0;Disopyramide, a type I antiarrhythmic drug, possesses potent negative inotropic and chronotropic effects. When administered with beta-blockers, disopyramide can cause severe bradycardia and torsades de pointes.<xref ref-type="bibr" rid="article-658.r26">[26]</xref></p>
        <p>Anesthetic agents: Careful consideration is essential when administering betaxolol with anesthetic agents that depress the myocardium, like isoflurane and propofol.<xref ref-type="bibr" rid="article-658.r27">[27]</xref></p>
      </sec>
      <sec id="article-658.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Betaxolol is contraindicated in heart blocks&#x000a0;(second-degree or greater), decompensated heart failure, sinus bradycardia, cardiogenic shock, and hypersensitivity reactions.<xref ref-type="bibr" rid="article-658.r7">[7]</xref><xref ref-type="bibr" rid="article-658.r28">[28]</xref><xref ref-type="bibr" rid="article-658.r29">[29]</xref><xref ref-type="bibr" rid="article-658.r30">[30]</xref></p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p>Bronchospastic diseases:&#x000a0;The lowest effective dose of betaxolol should be used cautiously, and a bronchodilator should be readily available. Higher doses of betaxolol should be avoided in patients with moderate to severe asthma or chronic obstructive pulmonary disease.&#x000a0;In patients with fluid retention, betaxolol should be avoided without the simultaneous addition of a diuretic.<xref ref-type="bibr" rid="article-658.r3">[3]</xref><xref ref-type="bibr" rid="article-658.r4">[4]</xref><xref ref-type="bibr" rid="article-658.r20">[20]</xref></p>
        <p>Myasthenia gravis: Betaxolol is avoided in patients with neuromuscular disease because of its potential to exacerbate muscle weakness in patients with myasthenia gravis.<xref ref-type="bibr" rid="article-658.r31">[31]</xref></p>
        <p>Angina pectoris exacerbation:&#x000a0;Abrupt betaxolol discontinuation may exacerbate angina pectoris; patients should be advised against interrupting therapy without medical advice.<xref ref-type="bibr" rid="article-658.r32">[32]</xref></p>
        <p>Major surgery:&#x000a0;Chronic beta-blocker treatment should not be stopped before major surgery to avoid complications during anesthesia. Ensure the betaxolol dosage is adjusted to maintain effective heart rate control without causing hypotension or bradycardia.<xref ref-type="bibr" rid="article-658.r33">[33]</xref></p>
        <p>Pheochromocytoma:&#x000a0;Betaxolol should not be administered in cases of untreated pheochromocytoma. Beta-blockers should not be initiated before ensuring adequate &#x003b1;-blockade because the absence of &#x003b2;-2-mediated vasodilation might cause severe unopposed &#x003b1;-mediated vasoconstriction, potentially resulting in a hypertensive crisis.<xref ref-type="bibr" rid="article-658.r34">[34]</xref><xref ref-type="bibr" rid="article-658.r35">[35]</xref></p>
        <p>Transthyretin amyloid cardiomyopathy: As per AHA/ACC,&#x000a0;guideline-directed medical therapy may be poorly tolerated in individuals diagnosed with transthyretin amyloid cardiomyopathy and an ejection fraction of 40% or lower.&#x000a0;Beta-blockers could worsen heart failure symptoms in transthyretin amyloid cardiomyopathy since the cardiac output depends on the heart rate.<xref ref-type="bibr" rid="article-658.r36">[36]</xref></p>
      </sec>
      <sec id="article-658.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Systemic betaxolol administration requires regular monitoring of vital signs. Pulmonary function tests should be monitored in patients with underlying asthma/COPD. The American Academy of Ophthalmology guidelines state that there is a 20% to 25% reduction in intraocular pressure with betaxolol. Important baseline diagnostic testing includes visual field evaluation, central corneal thickness measurement, and imaging of the optic nerve head, retinal nerve fiber layer, and macula. The response to treatment is monitored during follow-up by regular evaluation of the optic nerve appearance and quantitative measurement with visual field testing and imaging of the optic nerve head, retinal nerve fiber layer, and macula.<xref ref-type="bibr" rid="article-658.r37">[37]</xref>&#x000a0;A clinician should counsel and monitor the patient for the potential systemic adverse effects seen with betaxolol and other &#x003b2;-blockers for patients on both topical and oral forms. Punctal occlusion or eyelid closure for 2 minutes after topical drop instillation may decrease potential systemic absorption of the topical drop.<xref ref-type="bibr" rid="article-658.r4">[4]</xref>&#x000a0;If these adverse effects occur, the clinician should consider switching medications. Abrupt withdrawal of betaxolol might trigger a thyroid storm; close monitoring is essential.<xref ref-type="bibr" rid="article-658.r38">[38]</xref></p>
      </sec>
      <sec id="article-658.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>The hallmarks of &#x003b2;-blocker toxicity include hypotension and bradycardia. What separates these clinical signs from other antihypertensives like calcium channel blockers is the presence of concurrent hyperkalemia and hypokalemia. Additionally, CNS depression, altered mental status, decreased myocardial contractility, arrhythmia, and respiratory compromise may be observed.<xref ref-type="bibr" rid="article-658.r39">[39]</xref><xref ref-type="bibr" rid="article-658.r40">[40]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>As explained above, life-threatening symptoms may be observed; the first step in evaluating a patient with potential beta-blocker toxicity should be to address a patient's airway if needed. Atropine administration before intubation may be necessary to prevent the vagal parasympathetic response, which could exacerbate bradycardia. Magnesium sulfate and sodium bicarbonate are options for patients who develop QT prolongation. Glucagon and intravenous fluids are the first-line treatments of choice for hypotension and bradycardia and reversal of &#x003b2;-blocker toxicity. If the patient presents within 2 hours of ingestion, charcoal can help prevent the &#x003b2;-blocker's absorption from the gut. Gastric decontamination with lavage is also an option, albeit rarely used, for patients who ingested large amounts of the &#x003b2;-blockers or have severe symptoms.<xref ref-type="bibr" rid="article-658.r41">[41]</xref></p>
        <p>
<bold>Recommendations</bold>
</p>
        <p>Although betaxolol is a selective &#x003b2;-1 receptor antagonist, its overdose symptoms are similar to the other &#x003b2;-blockers,&#x000a0;including the nonselective agents. This similarity is because betaxolol loses its selectivity at higher therapeutic levels and begins to bind to &#x003b2;-2 and &#x003b2;-3 receptors.<xref ref-type="bibr" rid="article-658.r3">[3]</xref><xref ref-type="bibr" rid="article-658.r42">[42]</xref>&#x000a0;The overdose of &#x003b2;-blockers has links with depression. Two-thirds of people who overdosed on &#x003b2;-blockers were taking a medication that was not prescribed for them.<xref ref-type="bibr" rid="article-658.r39">[39]</xref>&#x000a0;Extracorporeal circulatory support may be necessary for a life-threatening overdose of betaxolol.<xref ref-type="bibr" rid="article-658.r43">[43]</xref></p>
      </sec>
      <sec id="article-658.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Although it is not the first-line agent in the treatment of open-angle glaucoma, topical betaxolol is a valuable topical medication in the field of ophthalmology. Comprehensive knowledge of indications, contraindications, and adverse effects, as well as the monitoring of betaxolol pharmacotherapy, is essential for all interprofessional healthcare team members.</p>
        <p>Any deviations&#x000a0;or adverse events should be reported to the ophthalmologist. A pharmacist serves as the bridge between the ophthalmologist and the primary care clinician caring for the patient. The pharmacist can recommend medical reconciliation to help ensure the safe treatment of a patient's ocular hypertension or open-angle glaucoma without affecting the treatment of a patient's other potential comorbidities. The pharmacist can also help educate nurses, clinician assistants, and clinicians not specializing in ophthalmology on administration, dosage, and possible adverse effects. An emergency room clinician should understand that betaxolol is a &#x003b2;-blocker and should be able to assess for &#x003b2;-blocker-related adverse effects, toxicity, and effective management. The primary care clinician should be aware of the patient's use of topical betaxolol and consider its potential adverse effects.&#x000a0;</p>
        <p>A systematic review explored modifiable factors influencing glaucoma medication adherence from patient and healthcare professional viewpoints. The results underscored the necessity for collaborative efforts between healthcare providers like pharmacists, ophthalmologists, general practitioners, and patients to improve adherence. The key suggestions involved treatment regimen selection, enhancing glaucoma awareness, and fostering stronger patient-healthcare professional relationships. The research stressed the critical role of coordination between healthcare practitioners and patients in effectively addressing adherence concerns in glaucoma.<xref ref-type="bibr" rid="article-658.r44">[44]</xref></p>
        <p>Although betaxolol is usually a tolerable and safe medication, it still has contraindications, adverse effects, and the potential for lethal toxicity. Every healthcare professional in the interprofessional team must comprehend their role and work together as a unit to ensure maximum safety and effectiveness of the treatment. Effective patient outcomes with betaxolol necessitate open communication and an interprofessional team approach involving clinicians, ophthalmologists, optometrists, and pharmacists.</p>
      </sec>
      <sec id="article-658.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=658&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=658">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/658/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=658">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-658.s11">
        <title>References</title>
        <ref id="article-658.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Onishchenko</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Isakov</surname>
                <given-names>IN</given-names>
              </name>
              <name>
                <surname>Kolbasko</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Makogon</surname>
                <given-names>SI</given-names>
              </name>
            </person-group>
            <article-title>[Initial combination therapy for primary open-angle glaucoma].</article-title>
            <source>Vestn Oftalmol</source>
            <year>2019</year>
            <volume>135</volume>
            <issue>2</issue>
            <fpage>32</fpage>
            <page-range>32-38</page-range>
            <pub-id pub-id-type="pmid">31215532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buckley</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Goa</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Clissold</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension.</article-title>
            <source>Drugs</source>
            <year>1990</year>
            <month>Jul</month>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-90</page-range>
            <pub-id pub-id-type="pmid">2202584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Tucker</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Sankar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Theetha Kariyanna</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <chapter-title>Selective Beta-1 Blockers</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">29763157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weinreb</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Aung</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Medeiros</surname>
                <given-names>FA</given-names>
              </name>
            </person-group>
            <article-title>The pathophysiology and treatment of glaucoma: a review.</article-title>
            <source>JAMA</source>
            <year>2014</year>
            <month>May</month>
            <day>14</day>
            <volume>311</volume>
            <issue>18</issue>
            <fpage>1901</fpage>
            <page-range>1901-11</page-range>
            <pub-id pub-id-type="pmid">24825645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chidlow</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Melena</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Osborne</surname>
                <given-names>NN</given-names>
              </name>
            </person-group>
            <article-title>Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists.</article-title>
            <source>Br J Pharmacol</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>130</volume>
            <issue>4</issue>
            <fpage>759</fpage>
            <page-range>759-66</page-range>
            <pub-id pub-id-type="pmid">10864881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stewart</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Konstas</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Kruft</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.</article-title>
            <source>Ophthalmology</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>115</volume>
            <issue>7</issue>
            <fpage>1117</fpage>
            <page-range>1117-1122.e1</page-range>
            <pub-id pub-id-type="pmid">18082886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gedde</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Vinod</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Muir</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Lind</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mansberger</surname>
                <given-names>SL</given-names>
              </name>
              <collab>American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Panel</collab>
            </person-group>
            <article-title>Primary Open-Angle Glaucoma Preferred Practice Pattern&#x000ae;.</article-title>
            <source>Ophthalmology</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>128</volume>
            <issue>1</issue>
            <fpage>P71</fpage>
            <page-range>P71-P150</page-range>
            <pub-id pub-id-type="pmid">34933745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>e13</fpage>
            <page-range>e13-e115</page-range>
            <pub-id pub-id-type="pmid">29133356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Writing Committee Members</collab>
              <name>
                <surname>Virani</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Bittner</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Demeter</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Fearon</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Kazi</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Kolte</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kumbhani</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>LoFaso</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mahtta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mark</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Minissian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Navar</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Piano</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Talbot</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Taqueti</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>van Diepen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wiggins</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic&#x000a0;Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2023</year>
            <month>Aug</month>
            <day>29</day>
            <volume>82</volume>
            <issue>9</issue>
            <fpage>833</fpage>
            <page-range>833-955</page-range>
            <pub-id pub-id-type="pmid">37480922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pal</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Guidelines for management of essential tremor.</article-title>
            <source>Ann Indian Acad Neurol</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>14</volume>
            <issue>Suppl 1</issue>
            <fpage>S25</fpage>
            <page-range>S25-8</page-range>
            <pub-id pub-id-type="pmid">21847325</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yen</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Topical betaxolol for treating relapsing paronychia with pyogenic granuloma-like lesions induced by epidermal growth factor receptor inhibitors.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>78</volume>
            <issue>6</issue>
            <fpage>e143</fpage>
            <page-range>e143-e144</page-range>
            <pub-id pub-id-type="pmid">29339238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ishikawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Goseki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yoshitomi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Effect and mechanism of betaxolol and timolol on vascular relaxation in isolated rabbit ciliary artery.</article-title>
            <source>Jpn J Ophthalmol</source>
            <year>2006</year>
            <season>Nov-Dec</season>
            <volume>50</volume>
            <issue>6</issue>
            <fpage>504</fpage>
            <page-range>504-508</page-range>
            <pub-id pub-id-type="pmid">17180523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lezama-Mart&#x000ed;nez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Valencia-Hern&#x000e1;ndez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Flores-Monroy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Aguilar</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Combination of &#x003b2; Adrenergic Receptor Block and Renin-Angiotensin System Inhibition Diminished the Angiotensin II-Induced Vasoconstriction and Increased Bradykinin-Induced Vasodilation in Hypertension.</article-title>
            <source>Dose Response</source>
            <year>2017</year>
            <season>Oct-Dec</season>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>1559325817737932</fpage>
            <pub-id pub-id-type="pmid">29162996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holl&#x000f3;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Whitson</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Faulkner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McCue</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wieland</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chastain</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>DeSantis</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Przydryga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dahlin</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Concentrations of betaxolol in ocular tissues of patients with glaucoma and normal monkeys after 1 month of topical ocular administration.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>235</fpage>
            <page-range>235-40</page-range>
            <pub-id pub-id-type="pmid">16384968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fayyaz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ranta</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Toropainen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vellonen</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Ricci</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Reinisalo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heikkinen</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Urtti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jamei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Del Amo</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits.</article-title>
            <source>Mol Pharm</source>
            <year>2020</year>
            <month>Feb</month>
            <day>03</day>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>588</fpage>
            <page-range>588-594</page-range>
            <pub-id pub-id-type="pmid">31794668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cacabelos</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Naidoo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Corzo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cacabelos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Carril</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.</article-title>
            <source>Int J Mol Sci</source>
            <year>2021</year>
            <month>Dec</month>
            <day>10</day>
            <volume>22</volume>
            <issue>24</issue>
            <pub-id pub-id-type="pmid">34948113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Huo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Sustained ophthalmic delivery of highly soluble drug using pH-triggered inner layer-embedded contact lens.</article-title>
            <source>Int J Pharm</source>
            <year>2018</year>
            <month>Jun</month>
            <day>10</day>
            <volume>544</volume>
            <issue>1</issue>
            <fpage>100</fpage>
            <page-range>100-111</page-range>
            <pub-id pub-id-type="pmid">29627356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <collab>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins&#x02014;Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>133</volume>
            <issue>1</issue>
            <fpage>e26</fpage>
            <page-range>e26-e50</page-range>
            <pub-id pub-id-type="pmid">30575676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <chapter-title>Betaxolol</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>9</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30000202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pozzi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>[True and presumed contraindications of beta blockers. Peripheral vascular disease, diabetes mellitus, chronic bronchopneumopathy].</article-title>
            <source>Ital Heart J Suppl</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>1</volume>
            <issue>8</issue>
            <fpage>1031</fpage>
            <page-range>1031-7</page-range>
            <pub-id pub-id-type="pmid">10993010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siddiqui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Judd</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Oparil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Calhoun</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Reserpine Substantially Lowers Blood Pressure in Patients With Refractory Hypertension: A Proof-of-Concept Study.</article-title>
            <source>Am J Hypertens</source>
            <year>2020</year>
            <month>Aug</month>
            <day>04</day>
            <volume>33</volume>
            <issue>8</issue>
            <fpage>741</fpage>
            <page-range>741-747</page-range>
            <pub-id pub-id-type="pmid">32179903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Handler</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects using combined rate-slowing antihypertensive agents.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>7</issue>
            <fpage>529</fpage>
            <page-range>529-32</page-range>
            <pub-id pub-id-type="pmid">21762367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lu</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Kam</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nordin</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Khelae</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Choy</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CY</given-names>
              </name>
            </person-group>
            <article-title>Beta-blocker use and risk of symptomatic bradyarrhythmias: a hospital-based case-control study.</article-title>
            <source>J Geriatr Cardiol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>749</fpage>
            <page-range>749-759</page-range>
            <pub-id pub-id-type="pmid">27899939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haase</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pietzsch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>F&#x000e4;hnrich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Voss</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Riethling</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Results of a systematic adverse drug reaction (ADR)-screening concerning bradycardia caused by drug interactions in departments of internal medicine in Rostock.</article-title>
            <source>Int J Clin Pharmacol Ther</source>
            <year>2002</year>
            <month>Mar</month>
            <volume>40</volume>
            <issue>3</issue>
            <fpage>116</fpage>
            <page-range>116-9</page-range>
            <pub-id pub-id-type="pmid">11911600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maideen</surname>
                <given-names>NMP</given-names>
              </name>
              <name>
                <surname>Rajkapoor</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Muthusamy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ramanathan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thangadurai</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Sughir</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>A Review on Pharmacokinetic and Pharmacodynamic Drug Interactions of Adrenergic &#x003b2;-blockers with Clinically Relevant Drugs-An Overview.</article-title>
            <source>Curr Drug Metab</source>
            <year>2021</year>
            <volume>22</volume>
            <issue>9</issue>
            <fpage>672</fpage>
            <page-range>672-682</page-range>
            <pub-id pub-id-type="pmid">34182907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tisdale</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management.</article-title>
            <source>Can Pharm J (Ott)</source>
            <year>2016</year>
            <month>May</month>
            <volume>149</volume>
            <issue>3</issue>
            <fpage>139</fpage>
            <page-range>139-52</page-range>
            <pub-id pub-id-type="pmid">27212965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meng</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Agrimi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Paolocci</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>WD</given-names>
              </name>
            </person-group>
            <article-title>Anesthetic Agents Isoflurane and Propofol Decrease Maximal Ca<sup>2+</sup>-Activated Force and Thus Contractility in the Failing Myocardium.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>371</volume>
            <issue>3</issue>
            <fpage>615</fpage>
            <page-range>615-623</page-range>
            <pub-id pub-id-type="pmid">31515443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alves</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Figueiredo</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Code&#x000e7;o</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Regateiro</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Gon&#x000e7;alo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A closer look at allergic contact dermatitis caused by topical ophthalmic medications.</article-title>
            <source>Contact Dermatitis</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>87</volume>
            <issue>4</issue>
            <fpage>331</fpage>
            <page-range>331-335</page-range>
            <pub-id pub-id-type="pmid">35715881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x000d6;zcan</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>G&#x000fc;ng&#x000f6;r</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Osmonov</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tekke&#x0015f;in</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Altay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ekmek&#x000e7;i</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Toprak</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yildirim</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>&#x000c7;alik</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Alper</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>G&#x000fc;rkan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Erdinler</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Management and outcome of topical beta-blocker-induced atrioventricular block.</article-title>
            <source>Cardiovasc J Afr</source>
            <year>2015</year>
            <season>Nov-Dec</season>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>210</fpage>
            <page-range>210-3</page-range>
            <pub-id pub-id-type="pmid">26659434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teerlink</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Alburikan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Metra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Acute decompensated heart failure update.</article-title>
            <source>Curr Cardiol Rev</source>
            <year>2015</year>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-62</page-range>
            <pub-id pub-id-type="pmid">24251454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khella</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Kozart</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Unmasking and exacerbation of myasthenia gravis by ophthalmic solutions: betoxolol, tobramycin, and dexamethasone. A case report.</article-title>
            <source>Muscle Nerve</source>
            <year>1997</year>
            <month>May</month>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>631</fpage>
            <pub-id pub-id-type="pmid">9140379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koracevic</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Micic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stojanovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tomasevic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kostic</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Velickovic Radovanovic</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lovic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Djordjevic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Randjelovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koracevic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ristic</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Beta blocker rebound phenomenon is important, but we do not know its definition, incidence or optimal prevention strategies.</article-title>
            <source>Hypertens Res</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>43</volume>
            <issue>7</issue>
            <fpage>591</fpage>
            <page-range>591-596</page-range>
            <pub-id pub-id-type="pmid">32382156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>London</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hur</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>WG</given-names>
              </name>
            </person-group>
            <article-title>Association of perioperative &#x003b2;-blockade with mortality and cardiovascular morbidity following major noncardiac surgery.</article-title>
            <source>JAMA</source>
            <year>2013</year>
            <month>Apr</month>
            <day>24</day>
            <volume>309</volume>
            <issue>16</issue>
            <fpage>1704</fpage>
            <page-range>1704-13</page-range>
            <pub-id pub-id-type="pmid">23613075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Myklejord</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Undiagnosed pheochromocytoma: the anesthesiologist nightmare.</article-title>
            <source>Clin Med Res</source>
            <year>2004</year>
            <month>Feb</month>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-62</page-range>
            <pub-id pub-id-type="pmid">15931336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garg</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Kharb</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brar</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Gundgurthi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Medical management of pheochromocytoma: Role of the endocrinologist.</article-title>
            <source>Indian J Endocrinol Metab</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>15 Suppl 4</volume>
            <issue>Suppl4</issue>
            <fpage>S329</fpage>
            <page-range>S329-36</page-range>
            <pub-id pub-id-type="pmid">22145136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dunlay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fedson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Hayek</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Khazanie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kittleson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Vardeny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vest</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2022</year>
            <month>May</month>
            <day>03</day>
            <volume>145</volume>
            <issue>18</issue>
            <fpage>e895</fpage>
            <page-range>e895-e1032</page-range>
            <pub-id pub-id-type="pmid">35363499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erkin</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Celik</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kayik&#x000e7;io&#x0011f;lu</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Deveci</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Sakar</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Effects of latanoprost and betaxolol on cardiovascular and respiratory status of newly diagnosed glaucoma patients.</article-title>
            <source>Ophthalmologica</source>
            <year>2006</year>
            <volume>220</volume>
            <issue>5</issue>
            <fpage>332</fpage>
            <page-range>332-7</page-range>
            <pub-id pub-id-type="pmid">16954712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>An&#x00131;k</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Beta-blocker Rebound Phenomenon in an Adolescent with Graves&#x02019; Disease.</article-title>
            <source>J Clin Res Pediatr Endocrinol</source>
            <year>2022</year>
            <month>Dec</month>
            <day>01</day>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>490</fpage>
            <page-range>490-491</page-range>
            <pub-id pub-id-type="pmid">35859995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r39">
          <label>39</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Khalid</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Galuska</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <chapter-title>Beta-Blocker Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">28846217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shepherd</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Treatment of poisoning caused by beta-adrenergic and calcium-channel blockers.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2006</year>
            <month>Oct</month>
            <day>01</day>
            <volume>63</volume>
            <issue>19</issue>
            <fpage>1828</fpage>
            <page-range>1828-35</page-range>
            <pub-id pub-id-type="pmid">16990629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lauterbach</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical toxicology of beta-blocker overdose in adults.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>125</volume>
            <issue>2</issue>
            <fpage>178</fpage>
            <page-range>178-186</page-range>
            <pub-id pub-id-type="pmid">30916882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kerns</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kline</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Beta-blocker and calcium channel blocker toxicity.</article-title>
            <source>Emerg Med Clin North Am</source>
            <year>1994</year>
            <month>May</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>365</fpage>
            <page-range>365-90</page-range>
            <pub-id pub-id-type="pmid">7910555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bilbault</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pynn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mathien</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mazzucotelli</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jaeger</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Near-fatal betaxolol self-poisoning treated with percutaneous extracorporeal life support.</article-title>
            <source>Eur J Emerg Med</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>120</fpage>
            <page-range>120-2</page-range>
            <pub-id pub-id-type="pmid">17496693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-658.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bott</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Subramanian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Edgar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lawrenson</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Barriers and enablers to medication adherence in glaucoma: A systematic review of modifiable factors using the Theoretical Domains Framework.</article-title>
            <source>Ophthalmic Physiol Opt</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>96</fpage>
            <page-range>96-114</page-range>
            <pub-id pub-id-type="pmid">37985237</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
